The content on this site is intended for healthcare professionals only
Dr Marlies Reimers talks with ecancer at the 2013 European Cancer Confernece in Amsterdam about how aspirin improves survival in patients diagnosed with colon cancer.
Although previous research has shown that taking low dose aspirin after being diagnosed with colon cancer improves patient outcome, the reasons why this happens remain unknown.
The new research has shown that aspirin improves outcome in patients whose tumour cells express a specific protein on their surface; the protein is known as Human Leukocyte Antigen class I (HLA class I), a cell-surface protein produced by a collection of genes involved in the functioning of the immune system.
The results mean that HLA class I could be used in the future to predict whether or not a patient would benefit from aspirin.
Read more on ecancerNews
ecancer's filming at ECC has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Immunotherapy significantly increases the number of patients free from bowel cancer
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
ESMO 2023: Highlights and analysis
Active surveillance for oesophageal cancer shows improved HRQoL compared to standard surgery
OncoAlert Round Up for August 4th - 10th, 2023
OncoAlert round up July 28th to August 3rd, 2023
